Faculty Profiles - KANDA Mitsuro

Papers - KANDA Mitsuro

Division display 301 - 320 of about 573 ／ All the affair displays >>

Expression, Function, and Prognostic Value of MAGE-D4 Protein in Esophageal Squamous Cell Carcinoma. Reviewed International journal

Uno Y, Kanda M, Sato Y, Shimizu D, Umeda S, Hattori N, Hayashi M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Motoyama S, Koike M, Kodera Y

Anticancer research Vol. 39 ( 11 ) page： 6015 - 6023 2019.11

Language：Japanese Publishing type：Research paper (scientific journal)

BACKGROUND/AIM: We previously reported that expression of melanoma-associated antigen (MAGE)-D4 mRNA was a prognostic factor for esophageal squamous cell carcinoma (ESCC). The aim of this study was to validate the expression of MAGE-D4 in two additional patient cohorts, and to investigate its biological functions. MATERIALS AND METHODS: The role of MAGE-D4 in cell proliferation, adhesion, and migration was determined by gene knockdown experiments in the KYSE590 cell line. MAGE-D4 protein expression was analyzed in ESCC tissues by immunohistochemistry. A second validation cohort consisted of an ESCC mRNA dataset from The Cancer Genome Atlas. RESULTS: Knockdown of MAGE-D4 significantly decreased cell proliferation and migration. Expression of MAGE-D4 protein was significantly associated with disease-free survival. In the second validation cohort, high MAGE-D4 mRNA expression was associated with significantly shorter overall survival and disease-free survival. CONCLUSION: MAGE-D4 plays an important role in the malignant behavior of ESCC. MAGE-D4 was validated as a prognostic indicator in two independent ESCC patient cohorts.

DOI： 10.21873/anticanres.13807

Web of Science

PubMed

Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset. Reviewed

Nakanishi K, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Murotani K, Kodera Y

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association Vol. 22 ( 6 ) page： 1215 - 1225 2019.11

Language：Japanese Publishing type：Research paper (scientific journal)

BACKGROUND: This study aimed to evaluate whether the timing of initiating postoperative chemotherapy with S-1 monotherapy affects gastric cancer patients' prognosis. METHODS: A multi-institution dataset identified patients with pStage II or III gastric cancer who received S-1 monotherapy for over 6 months after curative resection between 2010 and 2014. Patients were divided into three groups based on the timing of S-1 monotherapy initiation. Prognostic factors for relapse-free survival (RFS) were investigated. RESULTS: We classified 401 patients into groups as follows: S-1 administered within 6 weeks (n = 247), between 6 and 8 weeks (n = 95), and after 8 weeks (n = 59). The RFS times were not significantly different in the within 6 weeks group and the between 6 and 8 weeks group, but the after 8 weeks group had a shorter RFS time compared with the other two groups (within 6 weeks group vs. after 8 weeks group; P = 0.0044). By disease stage, this trend was the same. The multivariable analysis showed that a larger tumor size (≥ 50 mm), pStage III, and the after 8 weeks group were independent prognostic factors for RFS (after 8 weeks group: hazard ratio, 2.05; P = 0.0069). The prevalence of hematogenous metastasis as the initial recurrence site increased by delayed initiation of S-1. A forest plot revealed that delayed administration after 8 weeks was associated with a greater risk of recurrence in most subgroups. CONCLUSIONS: Postoperative chemotherapy with S-1 monotherapy for gastric cancer is recommended to begin within 8 weeks after surgery.

DOI： 10.1007/s10120-019-00961-9

Web of Science

PubMed

Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer. Reviewed International journal

Endo M, Kanda M, Sawaki K, Shimizu D, Tanaka C, Kobayashi D, Hattori N, Hayashi M, Yamada S, Koike M, Omae K, Kodera Y

Anticancer research Vol. 39 ( 11 ) page： 5903 - 5910 2019.11

Language：Japanese Publishing type：Research paper (scientific journal)

BACKGROUND: Gastric cancer (GC) exhibits heterogeneous clinical and molecular features, requiring the development of new biomarkers to further understand this disease. Our transcriptomic analysis detected overexpression of melanoma-associated antigen A6 (MAGEA6) in metastatic GC, leading us to determine the clinical significance of MAGEA6 in GC. MATERIALS AND METHODS: Fourteen GC cell lines and 230 pairs of surgically resected gastric tissues were subjected to mRNA expression analysis. Polymerase chain reaction array analysis was performed to identify coordinately expressed cancer-related genes, and immunohistochemistry (IHC) was used to detected MAGEA6 expression in situ. RESULTS: MAGEA6 mRNA levels were positively correlated with the expression of matrix metallopeptidase 9 mRNA. MAGEA6 mRNA levels were higher in GC tissues compared with those in normal adjacent tissues. Patients with high MAGEA6 expression had significantly worse prognosis. MAGEA6 protein levels in primary lesions predicted the likelihood of recurrence. CONCLUSION: Overexpression of MAGEA6 in GC tissues represents a promising biomarker for assessing the malignant phenotype of GC.

DOI： 10.21873/anticanres.13794

Web of Science

PubMed

Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer. Reviewed International journal

Sawaki K, Kanda M, Umeda S, Miwa T, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Omae K, Koike M, Kodera Y

Anticancer research Vol. 39 ( 11 ) page： 6125 - 6133 2019.11

Language：Japanese Publishing type：Research paper (scientific journal)

AIM: The aim of the study was to identify novel biomarkers that are vital for improving management of patients with gastric cancer (GC). MATERIALS AND METHODS: An RNA-sequencing analysis was conducted using gastric tissue from patients with metastatic GC. In vitro cell functions were evaluated by siRNA-mediated knockdown assays. A total of 230 pairs of gastric tissue were subjected to expression analysis of mRNA and protein in situ. The serum levels of the candidate biomarker were determined by ELISA. RESULTS: MELTF was identified as a candidate biomarker. Inhibition of MELTF expression suppressed the invasion ability of GC cells. Increased tissue MELTF mRNA expression was associated with shorter survival. Furthermore, staining intensity of tissue MELTF protein was linked to recurrence rates. Serum MELTF levels gradually were increased from healthy controls to advanced GC. Patients with high serum MELTF levels had poor prognosis. CONCLUSION: Both tissue and serum MELTF levels may serve as biomarkers of GC progression.

DOI： 10.21873/anticanres.13820

Web of Science

PubMed

妊娠を契機に急速増大を来したMCNと術前診断した膵リンパ管腫の一切除例 Reviewed

加藤吉康, 山田豪, 高見秀樹, 園原史訓, 猪川祥邦, 林真路, 服部憲史, 神田光郎, 小林大介, 田中千恵, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本消化器病学会東海支部例会プログラム抄録集 Vol. 131回 page： 75 - 75 2019.11

胃原発mixed adenoneuroendocrine carcinomaの1例 Reviewed

荘加道太, 清水大, 栗本景介, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 神田光郎, 田中千恵, 小林大介, 山田豪, 中山吾郎, 小池聖彦, 小寺泰弘

日本消化器病学会東海支部例会プログラム抄録集 Vol. 131回 page： 59 - 59 2019.11

分子生物学的手法を応用した微小腹腔内遊離胃癌細胞検出法 Reviewed

中西香企, 神田光郎, 梅田晋一, 田中千恵, 小林大介, 林真路, 服部憲史, 高見秀樹, 園原史訓, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本消化器外科学会雑誌 Vol. 52 ( Suppl.2 ) page： 102 - 102 2019.11

Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis. Reviewed International journal

Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Omae K, Kodera Y

BMC surgery Vol. 19 ( 1 ) page： 143 - 143 2019.10

Language：Japanese Publishing type：Research paper (scientific journal)

BACKGROUND: The global increase in elderly populations is accompanied by an increasing number of candidates for esophagectomy. Here we aimed to determine the postoperative outcomes after subtotal esophagectomy in elderly patients with esophageal cancer. METHODS: Patients (n = 432) with who underwent curative-intent transthoracic subtotal esophagectomy with 2- or 3-field lymphadenectomies for thoracic esophageal cancer were classified as follows: non-elderly (age < 75 years, n = 373) and elderly (age ≥ 75 years, n = 59) and groups. To balance the essential variables including neoadjuvant treatment and stage of progression, we conducted propensity score analysis, and clinical characteristics, perioperative course and prognosis were compared. RESULTS: After two-to-one propensity score matching, 100 and 50 patients were classified in the non-elderly and elderly groups. The elderly group had more comorbidities and lower preoperative cholinesterase activities and prognostic nutrition indexes. Although incidences of postoperative pneumonia, arrhythmia and delirium were slightly increased in the elderly group, no significant differences were observed in overall incidence of postoperative complications, rates of repeat surgery and death caused by surgery, and length of postoperative hospital stay between the two groups. There were no significant differences in disease-free and disease-specific survival as well as overall survival between the two groups. CONCLUSION: Older age (≥75 years) had limited impact on morbidity, disease recurrence, and survival after subtotal esophagectomy. Therefore, age should not prevent older patients from benefitting from surgery.

DOI： 10.1186/s12893-019-0617-2

Web of Science

PubMed

Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. Reviewed International journal

Sonohara F, Yamada S, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology Vol. 45 ( 10 ) page： 1895 - 1900 2019.10

Language：Japanese Publishing type：Research paper (scientific journal)

INTRODUCTION: In this study, we assessed the prognostic efficacy and feasibility of combined arterial resection (AR) for locally advanced pancreatic cancer (LAPC), and aimed to identify significant prognostic factors for patients who underwent combined AR. METHODS: Between 1981 and 2018, 733 consecutive patients who underwent pancreatic surgery for PC were identified. The 730 cases with detailed information were enrolled in the analysis. RESULTS: Among 730 resected PC patients, 44 (6%) underwent AR including 21 hepatic (48%), 12 celiac (27%), five splenic (12%), four superior mesenteric (9%), and two other arteries (4%). The combined AR surgery showed significantly longer operative time (median, 608 vs 451 min, P < 0.0001), and the incidence of intraoperative blood transfusion was significantly higher in AR than surgery without AR (P = 0.0002), whereas there was no significant difference in the intraoperative blood loss (970 vs 1200 mL, P = 0.2) and occurrence of major complications (P = 0.5). In prognostic analysis of AR cases, multivariate Cox proportional hazard models revealed preoperative and postoperative therapy were the independent factors for both recurrence-free survival (RFS) and overall survival (OS) (preoperative therapy: RFS, HR = 0.21, P = 0.007; OS, HR = 0.18, P = 0.01; postoperative therapy: RFS, HR = 0.31, P = 0.003; OS, HR = 0.19, P = 0.002). CONCLUSION: This study showed the feasibility of combined AR for LAPC and robust association of pre- and postoperative therapy and survival after AR surgery. Preoperative therapy following combined AR surgery is potentially powerful strategy for LAPC.

DOI： 10.1016/j.ejso.2019.05.019

Web of Science

PubMed

Risk Prediction of Postoperative Pneumonia After Subtotal Esophagectomy Based on Preoperative Serum Cholinesterase Concentrations. Reviewed International journal

Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Omae K, Kodera Y

Annals of surgical oncology Vol. 26 ( 11 ) page： 3718 - 3726 2019.10

Language：Japanese Publishing type：Research paper (scientific journal)

BACKGROUND: Patients undergoing subtotal esophagectomy for esophageal cancer frequently experience postoperative pneumonia. Development of preoperatively determined predictors for postoperative pneumonia will facilitate identifying high-risk patients and will assist with informing patients about their risk of postoperative pneumonia, enabling physicians to estimate with greater accuracy, will result in tailoring perioperative management. METHODS: Postoperative pneumonia was defined according to the revised Uniform Pneumonia Score. We analyzed the data for 355 patients to compare 32 potential predictive variables associated with postoperative pneumonia after subtotal esophagectomy. RESULTS: Forty-one patients (11.5%) had postoperative pneumonia. Preoperative cholinesterase (ChE) concentrations demonstrated the greatest area under the curve value (0.662) to predict postoperative pneumonia (optimal cutoff value = 217 IU/l). Univariate analysis identified a continuous value of preoperative ChE concentration as a significant risk factor for postoperative pneumonia (P = 0.0014). Multivariable analysis using factors potentially relevant to pneumonia revealed that preoperative ChE concentration was one of independent risk factors for pneumonia after esophagectomy (P = 0.008). Patients with low ChE concentrations were at increased risk of postoperative pneumonia in most patient subgroups. Moreover, the odds ratios of low ChE concentrations were highest in patients undergoing neoadjuvant treatment. A combination of preoperative serum ChE concentrations and Brinkman index stratified patients into low, intermediate, and high risk of postoperative pneumonia. CONCLUSIONS: Our findings indicate that preoperative ChE concentrations, particularly in combination with Brinkman index, may serve simply as a determined predictor of pneumonia after subtotal esophagectomy and may facilitate physicians' efforts to reduce the incidence of postoperative pneumonia.

DOI： 10.1245/s10434-019-07512-7

Web of Science

PubMed

Conversion Surgery施行例の予後因子から検討した切除不能胃癌に対する集学的治療戦略 Reviewed

小林大介, 神田光郎, 田中千恵, 清水大, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 57回 page： RT21 - 5 2019.10

DNAJC12の胃癌における役割についての検討 Reviewed

宇野泰朗, 神田光郎, 清水大, 田中千恵, 小林大介, 園原史訓, 服部憲史, 高見秀樹, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 57回 page： O7 - 4 2019.10

トランスレーショナルリサーチについて考える:臨床現場のアイデアをどう生かすか消化器外科医ならではの創薬シーズを求めて Reviewed

神田光郎, 清水大, 田中千恵, 小林大介, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本臨床外科学会雑誌 Vol. 80 ( 増刊 ) page： 360 - 360 2019.10

腹腔鏡下胃切除術におけるIndocyanine Green蛍光法を用いた病変位置同定方法 Reviewed

田中千恵, 神田光郎, 林真路, 服部憲史, 小林大介, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本臨床外科学会雑誌 Vol. 80 ( 増刊 ) page： 472 - 472 2019.10

胃癌根治切除術後S-1補助化学療法の忍容性予測因子の検討 Reviewed

三輪高嗣, 神田光郎, 田中千恵, 小林大介, 園原史訓, 高見秀樹, 服部憲史, 猪川祥邦, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本臨床外科学会雑誌 Vol. 80 ( 増刊 ) page： 570 - 570 2019.10

胃癌のおけるS-1術後補助化学療法開始時期と予後との関係多施設統合データベース Reviewed

中西香企, 神田光郎, 伊藤誠二, 望月能成, 寺本仁, 石榑清, 村井俊文, 浅田崇洋, 石山聡治, 松下英信, 田中千恵, 小林大介, 藤原道隆, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 57回 page： O56 - 1 2019.10

胃癌におけるETNK2のアポトーシスへの関与と肝転移形成の関連性 Reviewed

三輪高嗣, 神田光郎, 田中千恵, 小林大介, 園原史訓, 高見秀樹, 清水大, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 57回 page： O8 - 3 2019.10

日本のAYA世代のがん対策の方向性を読み解く Reviewed

栗本景介, 堀部敬三, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 神田光郎, 小林大介, 田中千恵, 山田豪, 中山吾郎, 小池聖彦, 清水千佳子, 高橋義行, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 57回 page： P166 - 5 2019.10

切除不能進行再発胃癌に対するnivolumab療法における好中球/リンパ球比の臨床的意義 Reviewed

小林大介, 清水大, 神田光郎, 田中千恵, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本臨床外科学会雑誌 Vol. 80 ( 増刊 ) page： 506 - 506 2019.10

英文論文について考える:方法論・重要性を中心に臨床外科医が英文論文を書く際の最初のハードルを越える定型化と剽窃回避 Reviewed

神田光郎, 清水大, 田中千恵, 小林大介, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本臨床外科学会雑誌 Vol. 80 ( 増刊 ) page： 346 - 346 2019.10

　 PREV - NEXT 　

<KANDA Mitsuro>

Papers - KANDA Mitsuro